OBJECTIVES The aim of this study was to determine the incidence, causes, and predictors of unplanned hospital readmissions after transcatheter aortic valve replacement (TAVR).
U nplanned readmissions after initial hospitalization are frequent, significantly affecting clinical outcomes, patient quality of life, and health care costs (1, 2) . Early (within 30 days of discharge) readmissions have generated significant debate. As many as 20% of Medicare beneficiaries are readmitted within 30 days after an index hospitalization, and this has been associated with additional health care costs exceeding $15 billion (1).
Of note, the rate of early unplanned readmissions has been considered a marker of quality of care and hospital performance (3, 4) , and the subject of provider payment restrictions in the United States. Identifying the timing, causes, and predictors of unplanned readmissions is thus fundamental for implementing appropriate preventive measures. However, data on unplanned readmissions after TAVR are scarce, particularly regarding the timing, specific causes, and predictors of readmission. More importantly, no data exist on 30-day readmissions after TAVR apart from reporting its incidence (6) (7) (8) .
The objectives of this study were to determine the incidence, causes, and predictive factors of unplanned hospital readmissions after TAVR, with a specific focus on readmissions within the 30-day and 1-year periods.
METHODS STUDY POPULATION.
A total of 893 consecutive patients with symptomatic severe aortic stenosis who underwent TAVR at 2 centers were evaluated for the study. Of these, patients who died before hospital discharge (n ¼ 65) or those with follow-up of less than 1 year (n ¼ 108) were excluded, leading to a final population of 720 patients. The indications for TAVR and procedural approach were assessed by each center's heart team composed of interventional cardiologists and cardiac surgeons. The TAVR procedures were performed using balloon-and self-expanding valves, as previously described (5) . In-hospital and follow-up data were prospectively entered in a dedicated database. Clinical outcomes were defined according to Valve Academic Research Consortium-2 criteria (9). All patients signed informed consent forms before the procedure, and all studies were performed in accordance with the local ethics committee of each center. 
RESULTS
The main baseline, procedural characteristics, and inhospital complications of the study population are shown in Table 1 . In a sensitivity analysis, we evaluated the impact of 30-day readmissions on 30-day to 2-year mortality.
The mortality rate at 2-year follow-up was 20.8% (95% CI: 17.5% to 24.1%). In those patients readmitted within 30 days after TAVR, the mortality rate at 2 years was 30.2% (95% CI: 20.4% to 40.0%) compared with 19.2% (95% CI: 15.7% to 22.7%) in those without 30-day readmission (log-rank p ¼ 0.002) ( Figure 3 ).
Early readmission was a factor associated with a higher mortality rate (30-day to 2-year) (HR: 1.89, 95% CI: 1.25 to 2.87; p ¼ 0.003), and this association persisted after adjusting for confounding factors in a multivariable analysis ( Table 5) .
DISCUSSION
Almost one-half of the patients undergoing TAVR were readmitted within the first year after the procedure, and about one-fourth of such readmissions occurred within the first 30 days post-TAVR (30-day readmission rate, w15%). Multiple readmissions were observed in more than one-third of such patients. Most (w60%) readmissions were due to noncardiac causes, with respiratory failure, infection, Nombela-Franco et al. Values are n (%) or n.
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COPD ¼ chronic obstructive pulmonary disease; PCI ¼ percutaneous coronary intervention; TAVR ¼ transcatheter aortic valve replacement. discharge, whereas the main factors associated with later rehospitalizations were patient comorbidities.
Periprocedural major bleeding events remain one of the most frequent complications of TAVR, and several studies have shown the high impact of such events on patient survival (26, 27, 38) . It is therefore not surprising that this periprocedural complication predicted early readmissions in our study. Additionally, a lower hemoglobin level at hospital discharge also played an important role in early readmissions. In fact, anemia has been well recognized as an important risk factor for hospital readmission (39), and we previously showed that the vast majority of TAVR patients have some degree of anemia at hospital discharge (40) . The interaction be- Tables 1 and 2 .
Nombela-Franco et al. Abbreviations as in Tables 1 through 3 . WHAT IS NEXT? The high readmission burden observed in this population should be taken into account so that specific preventive measures and postprocedural management to reduce readmission rates and costs and improve quality of life after TAVR can be implemented. Abbreviations as in Tables 1 through 3 .
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